NovaPoint Capital LLC Has $4.29 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

NovaPoint Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,856 shares of the company’s stock after acquiring an additional 942 shares during the period. Johnson & Johnson comprises 1.3% of NovaPoint Capital LLC’s holdings, making the stock its 26th largest holding. NovaPoint Capital LLC’s holdings in Johnson & Johnson were worth $4,288,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its stake in Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC lifted its stake in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp lifted its stake in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $4,390,037,000. Finally, Wellington Management Group LLP lifted its stake in Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock valued at $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $155.90 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a fifty day simple moving average of $153.65 and a 200 day simple moving average of $153.96. The company has a market capitalization of $375.11 billion, a PE ratio of 17.34, a P/E/G ratio of 2.35 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Raymond James Financial dropped their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Finally, Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.